Patent Application
20170146557
A paper copy of the sequence listing and a computer readable form of the same sequence listing are appended below and herein incorporated by reference. The information recorded in computer readable form is identical to the written sequence listing, according to 37 C.F.R. 1.821 (f).
The invention encompasses a method for determining Aβ metabolism in blood.
Alzheimer disease (AD) is the most common cause of dementia and is an increasing public health problem. It is currently estimated to afflict 5 million people in the United States, with an expected increase to 13 million by the year 2050. AD leads to loss of memory, cognitive function, and ultimately independence. AD takes a heavy personal and financial toll on the patient and the family. Because of the severity and increasing prevalence of the disease in the population, it is urgent that better treatments be developed and delivered at the earliest stage of the disease.
The application file contains at least one photograph executed in color. Copies of this patent application publication with color photographs will be provided by the Office upon request and payment of the necessary fee.
The present invention provides a method for determining Aβ metabolism by measuring Aβ turnover in a blood sample. As used herein, “turnover” refers in one embodiment to the rate of labeled Aβ production, the rate of labeled Aβ clearance, or a combination of both. In each instance, however, determining Aβ metabolism requires a measurement of labeled Aβ in a sample. In another embodiment, “turnover” refers to the half-life of Aβ in blood. As used herein, “Aβ” refers to total amyloidβ, an amyloidβ isoform such as Aβ38, Aβ40, or Aβ42, or a combination thereof. Advantageously, a method of the invention eliminates the need for a more difficult to obtain and invasive central nervous system sample to determine the metabolism of Aβ.
One aspect of the present invention is a method for determining Aβ metabolism in blood. Importantly, the turnover of Aβ in blood may reflect the metabolism of Aβ in the central nervous system. (This is contrary to steady-state blood Aβ levels, which have not been successfully correlated to central nervous system Aβ.) Generally speaking, measuring the turnover of Aβ in blood comprises administering a label to a subject, collecting a blood sample from the subject, and analyzing the sample to determine the turnover of Aβ in the sample. Each step is described in more detail below.
A method of the invention comprises, in part, administering a label to a subject. Suitable labels and suitable methods of administration are detailed below.
i. Labels
Suitable labels should allow the measurement of the turnover of Aβ in the blood. By way of non-limiting example, a suitable label may include a labeled amino acid or a labeled amino acid precursor. In one embodiment, the label may comprise at least one labeled amino acid. The amino acid may be naturally occurring, synthetic, or an amino acid analogue. In each instance, however, the amino acid should be capable of incorporation into Aβ to allow detection and quantification of the turnover of Aβ in blood. Non-limiting examples of natural amino acids may include alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine. In one embodiment, the amino acid may be an essential amino acid (e.g., an amino acid not produced by the body). In another embodiment, the amino acid may be a non-essential amino acid. In yet another embodiment, a label may comprise at least one essential amino acid and at least one non-essential amino acid. Generally, the choice of amino acid may be based on a variety of factors, including (1) whether the amino acid is present in at least one residue of the protein or peptide of interest; (2) whether the amino acid can quickly reach the site of protein synthesis; (3) whether the labeled amino acid affects the metabolism of the protein of interest (e.g., very large doses of leucine may affect muscle metabolism); and (4) the availability of the desired amino acid may be considered (i.e., some amino acids are much more expensive or harder to manufacture than others).
In some embodiments, a label may comprise at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, at least eighteen, at least nineteen, at least twenty, or more than twenty different kinds of labeled amino acids.
Amino acids may be labeled using any method known in the art, as long as the amino acid may be incorporated into Aβ and allows the detection of the turnover of Aβ in the blood. Labels may be radioactive or non-radioactive. For instance, in one embodiment, an amino acid may be labeled with a stable non-radioactive isotope. Non-limiting examples may include 2H, 13C, 15N, 17O, 18O, 33S, 34S, or 36S. Additionally, it is recognized that a number of other stable isotopes that change the mass of an atom by more or less neutrons than is seen in the prevalent native form would also be effective. In another embodiment, an amino acid may be labeled with more than one label (for instance, 13C and 15N).
In one embodiment, 13C6-phenylalanine, which contains six 13C atoms, may be used to label Aβ. In an exemplary embodiment, 13C6-leucine may be used to label Aβ. In yet another embodiment, a combination of a stable non-radioactive isotope and an amino acid listed in Table A may be used to label Aβ.
There are numerous commercial sources of labeled amino acids. Generally, the labeled amino acids may be produced either biologically or synthetically. Biologically produced amino acids may be obtained from an organism (e.g., kelp/seaweed) grown in an enriched mixture of 13C, 15N, or other isotope that is incorporated into amino acids as the organism produces proteins. The amino acids are then separated and purified. Alternatively, amino acids may be made with known synthetic chemical processes.
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
2H
13C
15N
17O and/or 18O
33S and/or 34S and/or 36S
ii. Methods of Administration
Suitable methods of administering a label may include any method that allows the measurement of the turnover of Aβ in blood. In one embodiment, a label may be administered parenterally, e.g. intravenously, intra-arterially, subcutaneously, intraperitoneally, or intramuscularly. In yet another embodiment, a label may be administered orally.
A label may be administered in several different ways, depending in part, on the type of label. In one embodiment, a label may be administered as an infusion over time. For instance, a label may be administered via an infusion for about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 minutes. Alternatively, a label may be administered via an infusion for about 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25, 7.5, 7.75, 8, 8.25, 8.5, 8.75, 9, 9.25, 9.5, 9.75, 10, 10.25, 10.5, 10.75, 11, 11.25, 11.5, 11.75, 12, 12.25, 12.5, or 12.75 hours. In still other embodiments, a label may be administered as an infusion for more than 13 hours. In an exemplary embodiment, the label may be administered as an IV infusion.
A label may also be administered in one or more boluses. For instance, a label may be administered in one bolus, two boluses, three boluses, four boluses, five boluses, or more than five boluses. Generally speaking, a bolus is a discrete administration for a duration of no longer than about 1 hour. In one embodiment, a bolus is administered in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 seconds. In another embodiment, a bolus is administered in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 minutes. The time between boluses may be seconds, minutes, hours, or days. For instance, the time between boluses may be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 sec. Alternatively, the time between boluses may be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 minutes. In another alternative, the time between boluses may be about 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25, 7.5, 7.75, 8, 8.25, 8.5, 8.75, 9, 9.25, 9.5, 9.75, 10, 10.25, 10.5, 10.75, 11, 11.25, 11.5, 11.75, 12, 12.25, 12.5, 12.75, 13, 13.25, 13.5, 13.75, 14, 14.25, 14.5,14.75, 15, 15.25, 15.5, 15.75, 16, 16.25, 16.5, 16.75, 17, 17.25, 17.5, 17.75, 18, 18.25, 18.5, 18.75, 19, 19.25, 19.5, 19.75, 20, 20.25, 20.5, 20.75, 21, 21.25, 21.5, 21.75, 22, 22.25, 22.5, 22.75, 23, 23.25, 23.5, 23.75, 24, 24.25, 24.5, 24.75, 25, 25.25, 25.5, 25.75, 26, 26.25, 26.5, 26.75, 27, 27.25, 27.5, 27.75, 28, 28.25, 28.5, 28.75, 29, 29.25, 29.5, 29.75, 30, or more than 30 hours.
In an exemplary embodiment, the label may be administered in at least one oral or IV bolus. In certain embodiments, a label may be administered via a combination of a bolus and an infusion. For instance, a subject may be administered a bolus of label, followed by an infusion of label.
Those of skill in the art will appreciate that the amount (or dose) of the label can and will vary, depending in part on the route of administration and the label used. Generally speaking, the amount should be sufficient to allow the measurement of Aβ turnover in blood. In some embodiments, if the label is administered via infusion, the amount may be between about 0.01 mg/kg/hr to about 4.5 mg/kg/hr. For instance, the amount may be about 0.001, 0.005, 0.01, 0.15, 0.2, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, or 4.5 mg/kg/hr. In other embodiments, if the label is administered via bolus, the amount may be between about 0.01 g to about 8 g. For example, the amount may be 0.001, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 7 or 8 g.
A method of the invention comprises, in part, collecting at least one blood sample from a subject. The blood sample typically contains labeled Aβ The sample may also contain unlabeled Aβ As used herein, “blood” refers to whole blood, plasma, or serum. Methods of collecting a blood sample are well known in the art. In an exemplary embodiment, venipuncture, with or without a catheter, may be used to collect a blood sample. In another exemplary embodiment, a finger stick, or the equivalent, may be used to collect a blood sample.
Generally speaking a blood sample is collected after the administration of a label, described in section I (a) above. A skilled artisan will appreciate that the time a blood sample is collected (after administration of a label) can and will vary depending on the label and the method of administering the label. In one embodiment, a blood sample is collected between about 1 min and about 48 hours after administration of a label. For instance, a blood sample may be collected between about 1 min and 48 hours, between about 1 min and 10 hours, or between about 1 min and 30 hours. In another embodiment, a blood sample may be collected between about 10 min and about 24 hours after administration of a label. In yet another embodiment, a blood sample may be collected between about 10 min and about 10 hours after administration of a label. For instance, a blood sample may be collected between about 15 min and 8 hours, between about 15 min and 6 hours, between about 15 min and 4 hours, between about 30 min and 5 hours, between about 1 hour and 5 hours, between about 1 hour and 4 hours, between about 2 hours and 4 hours, or between about 2 hours and 6 hours. In still another embodiment, a blood sample may be collected between about 10 hours and about 20 hours after administration of a label. For example, a blood sample may be collected between about 12 hours and 20 hours, between about 14 hours and 20 hours, between about 16 hours and 20 hours, or about 18 hours and 20 hours. In yet still another embodiment, a blood sample may be collected between about 20 hours and about 30 hours after administration of a label. For instance, a blood sample may be collected between about 22 hours and 28 hours or between about 24 hours and 28 hours. In an alternative embodiment, a blood sample may be collected after 30 hours after administration of a label. For instance, a blood sample may be collected after 30, 32, 34, 36, 38, 40, 42, 44, 46, 48 or greater than 48 hours after administration of a label.
In some embodiments, a blood sample may be collected after about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 sec after administration of a label. In other embodiments, a blood sample may be collected after about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 minutes after administration of a label. In certain embodiments, a blood sample may be collected after about 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25, 7.5, 7.75, 8, 8.25, 8.5, 8.75, 9, 9.25, 9.5, 9.75, 10, 10.25, 10.5, 10.75, 11, 11.25, 11.5, 11.75, 12, 12.25, 12.5, 12.75, 13, 13.25, 13.5, 13.75, 14, 14.25, 14.5,14.75, 15, 15.25, 15.5, 15.75, 16, 16.25, 16.5, 16.75, 17, 17.25, 17.5, 17.75, 18, 18.25, 18.5, 18.75, 19, 19.25, 19.5, 19.75, 20, 20.25, 20.5, 20.75, 21, 21.25, 21.5, 21.75, 22, 22.25, 22.5, 22.75, 23, 23.25, 23.5, 23.75, 24, 24.25, 24.5, 24.75, 25, 25.25, 25.5, 25.75, 26, 26.25, 26.5, 26.75, 27, 27.25, 27.5, 27.75, 28, 28.25, 28.5, 28.75, 29, 29.25, 29.5, 29.75, or 30 hours after administration of a label.
In exemplary embodiments, if the label is administered intravenously for about 9 hours, a blood sample may be collect between about one hour and about 15 hours, between about 5 hours and about 13 hours, or between about 8 hours and about ten hours after administration of the label. In one exemplary embodiment, if the label is administered intravenously, a blood sample may be collected about nine hours after administration of the label. In other exemplary embodiments, if the label is administered orally, a blood sample may be collected between about 30 min and about 5 hours or between about 1 hour and four hours after administration of the label. In a certain exemplary embodiment, if the label is administered orally, a blood sample may be collected about three hours after administration of the label.
More than one blood sample may be collected from a subject. For instance, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or more than 40 blood samples may be collected from a subject. The time between samples may be seconds, minutes, hours, or days. For instance, the time between samples may be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 sec. Alternatively, the time between samples may be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 23, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, or 120 minutes. In another alternative, the time between samples may be about 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 5.25, 5.5, 5.75, 6, 6.25, 6.5, 6.75, 7, 7.25, 7.5, 7.75, 8, 8.25, 8.5, 8.75, 9, 9.25, 9.5, 9.75, 10, 10.25, 10.5, 10.75, 11, 11.25, 11.5, 11.75, 12, 12.25, 12.5, 12.75, 13, 13.25, 13.5, 13.75, 14, 14.25, 14.5,14.75, 15, 15.25, 15.5, 15.75, 16, 16.25, 16.5, 16.75, 17, 17.25, 17.5, 17.75, 18, 18.25, 18.5, 18.75, 19, 19.25, 19.5, 19.75, 20, 20.25, 20.5, 20.75, 21, 21.25, 21.5, 21.75, 22, 22.25, 22.5, 22.75, 23, 23.25, 23.5, 23.75, 24, 24.25, 24.5, 24.75, 25, 25.25, 25.5, 25.75, 26, 26.25, 26.5, 26.75, 27, 27.25, 27.5, 27.75, 28, 28.25, 28.5, 28.75, 29, 29.25, 29.5, 29.75, 30, or more than 30 hours.
The blood sample should typically be large enough to allow the measurement of Aβ turnover. More than one sample may be pooled for a particular time point. In one embodiment, a blood sample may be about 50 μL to about 3000 μL. For instance, a blood sample may be about 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, or 3000 μL. In other embodiments, a blood sample may be more than 3000 μL.
A method of the invention comprises, in part, analyzing the sample to determine the turnover of Aβ in blood. Generally speaking, analyzing the sample encompasses (a) detecting and quantifying labeled and unlabeled Aβ in a blood sample and (b) deriving the turnover of Aβ from the quantity of labeled and unlabeled Aβ in the blood sample. Each step is discussed in more detail below.
i. Detecting and Quantifying Labeled and Unlabeled Aβ in a Blood Sample
The method of detecting and quantifying labeled and unlabeled Aβ in a blood sample can and will vary. For instance, detection methods will vary with the type of label used (e.g. radioactive or non-radioactive). In one embodiment, if a non-radioactive label is used, the detection method should be sensitive enough to detect changes in mass of the labeled protein with respect to the unlabeled protein. For instance, labeled and unlabeled Aβ may be detected with mass spectrometry. In one embodiment, the mass spectrometry protocol outlined in the Examples is used.
Additional techniques may be used to separate the labeled and unlabeled Aβ from other blood components, or to concentrate the labeled and unlabeled Aβ in a sample. For instance, labeled and unlabeled Aβ may be immunoprecipitated from a blood sample. Protocols for immunoprecipitations are known in the art. In one embodiment, the immunoprecipitation antibody may be attached to a solid support, such as a bead or resin. In another embodiment, the immunoprecipitation protocol detailed in the Examples may be used. Other methods of separating or concentrating Aβ may include chromatography. In particular, techniques linking a chromatographic step with a mass spectrometry step may be used.
To aid in detection and quantification of labeled and unlabeled Aβ, the Aβ may be divided into smaller peptides. For instance, Aβ may be digested with a protease to create several small peptides. In one embodiment, trypsin is used to digest Aβ.
Generally speaking, the method of detecting labeled and unlabeled Aβ may also be used to quantify the amount of labeled and unlabeled Aβ In some embodiments, quantification encompasses determining the ratio between labeled and unlabeled Aβ.
ii. Deriving the Turnover of Aβ
From the detection and quantification step outlined above, the turnover of Aβ may be derived. As used herein, “turnover” refers in one embodiment to the rate of labeled Aβ production, the rate of labeled Aβ clearance, or a combination of both. In another embodiment, “turnover” refers to the half-life of Aβ in blood. In still another embodiment, “turnover” refers to the product of the percent labeled Aβ and the absolute quantitation value of Aβ. For instance, “turnover” may refer to the product of the percent labeled Aβ42 to the absolute quantitation value of Aβ42.
Turnover may be calculated, in part, from the change over time in labeled, unlabeled or ratio of labeled to unlabeled Aβ. In other embodiments, turnover may be determined from the peak of labeled Aβ. In still other embodiments, fractional synthesis rate, fractional clearance rate, absolute synthesis rate, absolute clearance rate, half-life, decay rate, or compartmental modeling may be used to determine turnover. In each embodiment, turnover may be calculated using the in vivo labeled Aβ, in vivo unlabled Aβ, the ex vivo internal standard (absolute quantitation), or a combination thereof.
An alternative embodiment of the invention encompasses a kit. The kit typically comprises a solution of at least one labeled amino acid. In one embodiment, the solution is a shake or drink that may be consumed orally. The kit also contains instructions for administering the labeled amino acid solution and subsequently collecting at least one blood sample. The kit may also contain a container and/or paraphernalia for collecting and storing the blood sample. Additionally, the kit may contain an internal standard to ensure that that blood sample is of adequate quality to be analyzed for Aβ turnover and for absolute quantitation of labeled and unlabeled Aβ.
Yet another aspect of the present application encompasses a business method. Generally speaking, the method comprises distributing a kit of the invention to either a physician or individual. After the kit is used to collect a sample from the subject following the directions included in the kit, the sample is then returned to a lab for processing using a method of the invention.
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventors to function well in the practice of the invention. Those of skill in the art should, however, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments that are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention, therefore all matter set forth or shown in the accompanying drawings is to be interpreted as illustrative and not in a limiting sense.
As used herein, “bolus” refers to a discrete dosing of label. More than one bolus may be used to administer a label, but each bolus is a discrete dose. This is in contrast to an infusion, which is a continuous dose administered over time.
As used herein, “central nervous system” refers to the brain, cerebral spinal fluid, or any other tissue or fluid of the central nervous system where Aβ may be found.
As used herein, “infusion” refers to a continuous dosing of label over time. In some embodiments, the rate of the dosing may change over time.
As used herein, “metabolism” refers to any combination of the synthesis, transport, breakdown, modification, or clearance rate of a biomolecule.
As used herein, “subject” refers to any subject that has a central nervous system. In exemplary embodiments, “subject” refers to any subject that is susceptible to a disease or disorder characterized by amyloid plaques. In one exemplary embodiment, “subject” refers to an individual with AD or an individual that is at risk for AD. In another exemplary embodiment, “subject” refers to an individual that is advanced in age.
The following examples illustrate various iterations of the invention.
A pioneering approach was recently developed to directly measure Aβ metabolism in the central nervous system of living humans (Bateman et. al 2006). This method requires participants be admitted to a research hospital room, and have two IV catheters and a lumbar spinal catheter placed so that hourly samples of blood and cerebral-spinal fluid can be obtained. Using this method, recent studies have demonstrated that Aβ has a rapid metabolism (half-life of 8-10 hours) in the human brain and cerebral-spinal fluid (CSF).
Blood Aβ dynamics, however, are not well understood as previously there was no method to measure labeled Aβ within blood. If such a method were available, the physiology (and pathophysiology) of Aβ could be better understood as a quantitative measure of Aβ production in the brain, transport to blood and cerebral-spinal fluid, and clearance from blood. A blood labeled Aβ assay would allow for the physiology and pathophysiology of Aβ to be measured without invasive spinal catheters.
A stable isotope labeling kinetics immunoprecipitation-mass spectrometry approach was developed to measure labeled blood Aβ This provides the ability to measure blood Aβ production, transport between compartments, and clearance rates in humans.
The half-life of blood/plasma Aβ is distinctly different than in the CNS/CSF, with a t1/2 of 1 to 3 hours in production (
1. Samples thawed on ice.
2. Add 20 μl of Complete Protease Inhibitors (Roche, 1 tab dissolved in 1 ml water)
3. Centrifuge at 14,000 RPM at 4° C. for 15 minutes to remove particulates.
4. Pool the supernatants.
5. Dilute media standards into PBS.
6. Wash HJ5.1 (Aβ specific antibody) beads twice with 1× PBS with 0.02% azide. Make 50% bead slurry at the end.
7. Add 220 μl 5M guanidine hydrochloride solution.
8. Add 20 ul Tween-20 (5% in PBS for 0.05% final)
9. Add 5 ul of ISTD (N15-Aβ).
10.Add 30 μl antibody-beads (50% slurry enough for ˜20 ng Aβ).
11. Incubate overnight at 4° C.
12. Centrifuge beads at 4500 RPM for 5 minutes.
13. Remove supernatant into a new tube and save (plasma only).
14. Add 1 ml 0.5M guanidine hydrochloride solution
15. Add 10 ul of 5% for 0.05% final Tween-20.
16. Once re-suspended transfer beads to 1.5 ml tube.
17. Centrifuge beads at 4500 RPM for 5 minutes.
18. Discard supernatant.
19. Wash the beads two times with 1× AmBiC rinse. Discard the supernant and dry beads
20.Add 50 μl (bead volume) 98% formic acid (elution solution) and centrifuge beads. Remove supernatant and place in 1.5 ml tube.
21. Dry the elution solution in a speedvac for 1 hour to remove formic acid (37° C.).
23. Thaw 20 μg trypsin. Add 1 ml of 25 mM AmBiC solution to re-suspend the trypsin to a final concentration of 20 ng/ul.
24. Re-suspend the proteins in 10 ul solution of 25 mM AmBiC.
25. Add 10 μl of the 20 ng/μl trypsin solution to the beads for digestion.
26. Digest O/N (16 hrs) at 37° C. in the incubator.
27. Perform a short spin of the samples to let condensate settle at the bottom of tube.
28. Add 2 ul of formic acid to the digest (to precipitate proteins)
29. Mix samples.
30. Centrifuge the tryptic digest at 14,000 RPM at 4° C. for 15 minutes.
31. Transfer to autosampler vials then spin down samples using the speedvac and keep in the refrigerator at 4° C.
The samples were then analyzed by mass spectrometry as follows:
The amino acid sequence of Aβ 1-42 is DAEFRHDSGYEVHH QKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO:1) and Aβ 1-40 is DAEFRHDSGYEVH HQKLVFFAEDVGSNKGAIIGLMVGGVV (SEQ ID NO:2). When it is digested with a protease like trypsin, four smaller peptides are generated as Aβ 1-5 DAEFR (SEQ ID NO:3), Aβ 6-16 HDSGYEVHHQK (SEQ ID NO:4), Aβ 17-28 LVFFAEDVGSNK (SEQ ID NO:5), and Aβ 29-42 GAIIGLMVGGVVIA (SEQ ID NO:6). Only two of these peptides are of relevance for quantitation using the SILK technology (Stable Isotope Labeling Kinetics-Bateman et. al 2009) with leucine labeling because their sequence includes a leucine residue that can be labeled in vivo. These peptides are Aβ 17-28 LVFFAEDVGSNK (SEQ ID NO:5), and Aβ 29-42 GAIIGLMVGGVVIA (SEQ ID NO:6), but we use only the Aβ 17-28 LVFFAEDVGSNK (SEQ ID NO:5) peptide because it represents the total amounts of Aβ in the blood and produces a higher signal. Of course, it may be useful to also quantify the c-terminal (Aβ 29-42 GAIIGLMVGGVVIA (SEQ ID NO:6) or Aβ 29-40 GAIIGLMVGGVV (SEQ ID NO:7)) or n-terminal fragments in the blood as well. In general, any amino acid label can be used, any endoprotease can be used (or none at all) to label Aβ & quantify the label in the blood.
Experiments were performed on a TSQ Vantage mass spectrometer coupled to a nanoflow ESI source and a nano-2D liquid chromatography (NanoLC-2D). The samples were maintained at a temperature of 4° C. in the autosampler tray. Samples were injected onto a home-made nano column (150-mm diameter) with a pulled tip, packed to 15 cm with Ace 5 C18 AR column packing material (MAC-MOD Analytical, Chadds Ford, PA). Peptides were separated by the Nano2D-LC (Eksigent, Inc. Ultra NanoLC-2D) at a flow rate of 1 mL/min. Solvent A was 0.1% formic acid in water and solvent B was 0.1% formic acid in acetonitrile. The gradient was 15% B to 25% B in 10 min followed by 25% B to 95% B in 5 min, then, ramped down to 15% B in 2 min and the column re-equilibrated for 3 min while the autosampler was picking another sample for injection.
The TSQ Vantage mass spectrometer (MS) was operated in positive ion mode using a spray voltage of 1.2 kV, with optimized parameters from tuning with peptides. Data was acquired in Multiple Reaction Monitoring (MRM) mode. During this MRM experiments, the mass of the peptide was first detected in the first dimension, or as MS1. While MS1 is used to perform quantitation, the technique suffers from lack of specificity especially in very complex matrices like blood and due to the fact that many peptides have the same intact mass. The peptide ions were fragmented and detected in the mass spectrometer and this second dimension of MS fragmentation (MS2) provided unique fragments. The combination of the specific precursor mass and the unique fragment ions were used to selectively monitor the peptide to be quantified. In this case, multiple fragment ions (also known as reactions) were selectively monitored to quantitate Aβ 17-28, resulting in a unique MRM experiment. Aβ 17-28 has a precursor mass (MS1) with a charge to mass ratio of 663.340 for the endogenous peptide and 666.340 for the label incorporated peptide. Three each of their fragment ions were monitored after the MS2 fragmentation. The fragment ions also known as transition ions monitored have a mass to charge ratios of 819.38, 966.45 and 1113.52. The MRM experiments are detected and plotted as single chromatographic peaks which were processed by Xcalibur, which is the instrument control software.
This invention was made with government support under AG030946 awarded by the National Institutes of Health. The government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 61347554 | May 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13699497 | Jan 2013 | US |
| Child | 15422165 | US |
